J&J bets $2.6B on in vivo CAR-T tech

Good morning, healthcare professional.

Johnson & Johnson is placing a nearly $2.6 billion wager on technology that could transform cancer treatment, while regulatory decisions on novel therapies and major policy changes are reshaping the healthcare landscape. From breakthrough immunotherapies to contentious Medicaid reforms, today's developments will influence how millions access and receive care.

These stories highlight the collision of scientific innovation, regulatory oversight, and policy implementation that defines modern healthcare. The decisions being made now - in boardrooms, courtrooms, and advisory committees - will determine which treatments reach patients and who can afford them.

In today's healthcare digest:

• Johnson & Johnson secures option to acquire in vivo CAR-T developer for $2.6 billion
• FDA advisory committee supports Replimune's oncolytic virus therapy despite agency concerns
• Federal judge allows Medicaid work requirements to proceed amid implementation confusion
• FTC files lawsuit against Hims & Hers alleging privacy violations and deceptive practices

J&J Bets Big on Next-Generation CAR-T Technology

Johnson & Johnson has obtained an option to acquire Sail Biomedicines for nearly $2.6 billion, marking a major investment in 'in vivo' CAR-T technology. This approach programs immune cells directly inside patients' bodies, potentially eliminating the complex manufacturing process that makes current CAR-T therapies costly and inaccessible.

Unpacked:

• The deal represents one of the largest biotech acquisition options in 2026 and signals growing pharma confidence in this platform.
• Current CAR-T therapies require extracting patient cells, engineering them in specialized facilities, and reinfusing them weeks later at costs exceeding $400,000.
• In vivo CAR-T could dramatically expand patient access by reducing manufacturing complexity, treatment timelines, and overall costs.
• Sail's technology programs T-cells directly within the body using targeted delivery systems, avoiding external cell manipulation entirely.

FDA Panel Backs Replimune Melanoma Drug Despite Agency Criticism

An FDA advisory committee voted in favor of Replimune's oncolytic virus therapy for melanoma, even after agency reviewers raised concerns about the supporting clinical data. The experimental treatment uses engineered viruses to selectively attack cancer cells.

Unpacked:

• FDA reviewers questioned the strength of evidence from Replimune's clinical trials, creating tension with the committee's positive recommendation.
• Oncolytic virus therapies represent an emerging immunotherapy approach that harnesses modified viruses to destroy tumors and stimulate immune responses.
• Advisory committee votes typically predict final FDA decisions, though the agency is not bound by committee recommendations.
• If approved, this would become the first oncolytic immunotherapy specifically authorized for melanoma treatment.

Medicaid Work Requirements Proceed Despite Implementation Chaos

A federal judge has denied states' motion to postpone new Medicaid work requirements, allowing the controversial policy to take effect despite widespread confusion. Chronically ill patients face particular uncertainty about qualifying for the 'medically frail' exemption that would protect their coverage.

Unpacked:

• The decision affects millions of Medicaid beneficiaries who must now document work activities or qualify for exemptions to maintain coverage.
• Unclear guidance on medical frailty exemptions leaves chronically ill populations uncertain whether their conditions qualify for protection.
• Healthcare advocates warn the bureaucratic requirements could cause coverage losses among vulnerable groups struggling to navigate new processes.
• States requested delays citing inadequate time to build systems for tracking compliance and processing exemption applications.

FTC Sues Hims & Hers Over Privacy and Marketing Practices

The Federal Trade Commission has filed a lawsuit against telehealth company Hims & Hers, alleging the company misled consumers and violated privacy rights through deceptive business practices. The action represents increased regulatory scrutiny of the rapidly growing direct-to-consumer telehealth sector.

Unpacked:

• Specific allegations include misleading marketing claims and improper handling of sensitive health information collected through the platform.
• The telehealth industry expanded dramatically during the pandemic, often outpacing regulatory frameworks designed for traditional healthcare delivery.
• This case could establish important precedents for data privacy standards and marketing transparency requirements across digital health companies.
• Hims & Hers operates a prominent direct-to-consumer platform offering treatments for conditions including hair loss, sexual health, and mental health.

The Shortlist

• Alnylam shares plunged 29% after the company cut its 2026 outlook for Amvuttra, disappointing investors with weaker-than-expected sales projections.

• Capricor's Duchenne cell therapy was voted down by an FDA advisory panel, dealing a setback to the company's experimental treatment for cardiomyopathy.

• Lilly and Resilience committed $750 million to boost U.S. production capacity for diabetes and obesity medications amid surging demand.

• Regeneron posted its biggest quarter since the pandemic, fueled by booming Dupixent sales across multiple indications.

• Pfizer submitted Litfulo to regulators for vitiligo treatment, setting up a competitive challenge against Incyte and AbbVie in the dermatology market.